Bang-Bin Chen1,2, Yen-Shen Lu3,4, Chih-Wei Yu1,2, Ching-Hung Lin3,4, Tom Wei-Wu Chen3,4, Shwu-Yuan Wei1, Ann-Lii Cheng3,4, Tiffany Ting-Fang Shih5,6. 1. Department of Radiology, College of Medicine, National Taiwan University, Taipei, Taiwan. 2. Department of Medical Imaging, National Taiwan University Hospital, No. 7, Chung-Shan South Rd, Taipei, 10016, Taiwan. 3. Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan. 4. Department of Internal Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan. 5. Department of Radiology, College of Medicine, National Taiwan University, Taipei, Taiwan. ttfshih@ntu.edu.tw. 6. Department of Medical Imaging, National Taiwan University Hospital, No. 7, Chung-Shan South Rd, Taipei, 10016, Taiwan. ttfshih@ntu.edu.tw.
Abstract
OBJECTIVES: The aim of this study is to investigate the correlation of survival outcomes with imaging biomarkers from multiparametric magnetic resonance imaging (MRI) in patients with brain metastases from breast cancer (BMBC). METHODS: This study was approved by the institutional review board. Twenty-two patients with BMBC who underwent treatment involving bevacizumab on day 1, etoposide on days 2-4, and cisplatin on day 2 in 21-day cycles were prospectively enrolled for a phase II study. Three brain MRIs were performed: before the treatment, on day 1, and on day 21. Eight imaging biomarkers were derived from dynamic contrast-enhanced MRI (Peak, IAUC60, Ktrans, kep, ve), diffusion-weighted imaging [apparent diffusion coefficient (ADC)], and MR spectroscopy (choline/N-acetylaspartate and choline/creatine ratios). The relative changes (Δ) in these biomarkers were correlated with the central nervous system (CNS)-specific progression-free survival (PFS) and overall survival (OS) using the Kaplan-Meier and Cox proportional hazard models. RESULTS: There were no significant differences in the survival outcomes as per the changes in the biomarkers on day 1. On day 21, those with a low ΔKtrans (p = 0.024) or ΔADC (p = 0.053) reduction had shorter CNS-specific PFS; further, those with a low ΔPeak (p = 0.012) or ΔIAUC60 (p = 0.04) reduction had shorter OS compared with those with high reductions. In multivariate analyses, ΔKtrans and ΔPeak were independent prognostic factors for CNS-specific PFS and OS, respectively, after controlling for age, size, hormone receptors, and performance status. CONCLUSIONS: Multiparametric MRI may help predict the survival outcomes in patients with BMBC. KEY POINTS: • Decreased angiogenesis after chemotherapy on day 21 indicated good survival outcome. • ΔK trans was an independent prognostic factors for CNS-specific PFS. • ΔPeak was an independent prognostic factors for OS. • Multiparametric MRI helps clinicians to assess patients with BMBC. • High-risk patients may benefit from more intensive follow-up or treatment strategies.
OBJECTIVES: The aim of this study is to investigate the correlation of survival outcomes with imaging biomarkers from multiparametric magnetic resonance imaging (MRI) in patients with brain metastases from breast cancer (BMBC). METHODS: This study was approved by the institutional review board. Twenty-two patients with BMBC who underwent treatment involving bevacizumab on day 1, etoposide on days 2-4, and cisplatin on day 2 in 21-day cycles were prospectively enrolled for a phase II study. Three brain MRIs were performed: before the treatment, on day 1, and on day 21. Eight imaging biomarkers were derived from dynamic contrast-enhanced MRI (Peak, IAUC60, Ktrans, kep, ve), diffusion-weighted imaging [apparent diffusion coefficient (ADC)], and MR spectroscopy (choline/N-acetylaspartate and choline/creatine ratios). The relative changes (Δ) in these biomarkers were correlated with the central nervous system (CNS)-specific progression-free survival (PFS) and overall survival (OS) using the Kaplan-Meier and Cox proportional hazard models. RESULTS: There were no significant differences in the survival outcomes as per the changes in the biomarkers on day 1. On day 21, those with a low ΔKtrans (p = 0.024) or ΔADC (p = 0.053) reduction had shorter CNS-specific PFS; further, those with a low ΔPeak (p = 0.012) or ΔIAUC60 (p = 0.04) reduction had shorter OS compared with those with high reductions. In multivariate analyses, ΔKtrans and ΔPeak were independent prognostic factors for CNS-specific PFS and OS, respectively, after controlling for age, size, hormone receptors, and performance status. CONCLUSIONS: Multiparametric MRI may help predict the survival outcomes in patients with BMBC. KEY POINTS: • Decreased angiogenesis after chemotherapy on day 21 indicated good survival outcome. • ΔK trans was an independent prognostic factors for CNS-specific PFS. • ΔPeak was an independent prognostic factors for OS. • Multiparametric MRI helps clinicians to assess patients with BMBC. • High-risk patients may benefit from more intensive follow-up or treatment strategies.
Entities:
Keywords:
Breast cancer; Diffusion magnetic resonance imaging; Magnetic resonance spectroscopy; Neovascularization, pathologic; Survival analysis
Authors: James P B O'Connor; Alan Jackson; Geoff J M Parker; Caleb Roberts; Gordon C Jayson Journal: Nat Rev Clin Oncol Date: 2012-02-14 Impact factor: 66.675
Authors: Whitney B Pope; Hyun J Kim; Jing Huo; Jeffry Alger; Matthew S Brown; David Gjertson; Victor Sai; Jonathan R Young; Leena Tekchandani; Timothy Cloughesy; Paul S Mischel; Albert Lai; Phioanh Nghiemphu; Syed Rahmanuddin; Jonathan Goldin Journal: Radiology Date: 2009-07 Impact factor: 11.105
Authors: Roberto García-Figueiras; Sandra Baleato-González; Anwar R Padhani; Laura Oleaga; Joan C Vilanova; Antonio Luna; Juan Carlos Cobas Gómez Journal: Diagn Interv Radiol Date: 2016 Jan-Feb Impact factor: 2.630
Authors: Nils D Arvold; Kevin S Oh; Andrzej Niemierko; Alphonse G Taghian; Nancy U Lin; Rita F Abi-Raad; Meera Sreedhara; Jay R Harris; Brian M Alexander Journal: Breast Cancer Res Treat Date: 2012-09-12 Impact factor: 4.872
Authors: Natalie R Boonzaier; Timothy J Larkin; Tomasz Matys; Anouk van der Hoorn; Jiun-Lin Yan; Stephen J Price Journal: Radiology Date: 2017-02-27 Impact factor: 11.105
Authors: Benjamin M Ellingson; Eunhee Kim; Davis C Woodworth; Helga Marques; Jerrold L Boxerman; Yair Safriel; Robert C McKinstry; Felix Bokstein; Rajan Jain; T Linda Chi; A Gregory Sorensen; Mark R Gilbert; Daniel P Barboriak Journal: Int J Oncol Date: 2015-02-11 Impact factor: 5.650
Authors: Sarah J Nelson; Yan Li; Janine M Lupo; Marram Olson; Jason C Crane; Annette Molinaro; Ritu Roy; Jennifer Clarke; Nicholas Butowski; Michael Prados; Soonmee Cha; Susan M Chang Journal: J Neurooncol Date: 2016-08-17 Impact factor: 4.130
Authors: Christina Messiou; Matthew Orton; Joo Ern Ang; David J Collins; Veronica A Morgan; Dorothy Mears; Isabel Castellano; Dionysis Papadatos-Pastos; Andre Brunetto; Nina Tunariu; Helen Mann; Jean Tessier; Helen Young; Dana Ghiorghiu; Sarah Marley; Stan B Kaye; Johann S deBono; Martin O Leach; Nandita M deSouza Journal: Radiology Date: 2012-08-13 Impact factor: 11.105
Authors: Catherine Coolens; Matt N Gwilliam; Paula Alcaide-Leon; Isabella Maria de Freitas Faria; Fabio Ynoe de Moraes Journal: Cancers (Basel) Date: 2021-05-23 Impact factor: 6.639